Q4 2024 Organon & Co Earnings Call Transcript
Key Points
- Organon & Co (OGN) reported a 3% revenue growth at constant currency for the full year 2024, marking the third consecutive year of growth.
- The women's health franchise grew by 5%, driven by NexPlanar's 17% increase, positioning it to achieve at least $1 billion in revenue in 2025.
- The biosimilar franchise saw a 12% growth at constant currency, with strong performance in Brazil and plans for future launches.
- Organon & Co (OGN) achieved an adjusted EBITDA margin of 31.8%, reflecting a half-point margin expansion over the previous year.
- The company is implementing cost-saving initiatives expected to yield $200 million in savings in 2025, with a focus on operational efficiency and profitability.
- Organon & Co (OGN) faces a $200 million revenue headwind in 2025 due to the loss of exclusivity for a major product in Europe.
- Pricing pressures are expected to result in a $150 million to $180 million impact in 2025, driven by competitive dynamics and mandatory pricing revisions.
- The company anticipates a 300 basis point headwind from foreign exchange in 2025, affecting overall revenue growth.
- Adjusted gross margin decreased to 61.6% in 2024 from 62.7% in 2023, due to unfavorable pricing and higher inflation impacts.
- Organon & Co (OGN) expects significant one-time costs related to restructuring and manufacturing separation from Merck, impacting financials in 2025.
Thank you for standing by mainly [MRIdian] and I will be your conference operator today. At this time, I would like to welcome everyone to the Organon Fourth Quarter and Full Year 2024 for earnings call. (Operator instructions)
I would now like to turn the call over to Juan.
Good morning, everyone. Thank you for joining Organon Fourth Quarter and Full Year 2024 earnings call. With me today are Kevin Ali, Organon's Chief Executive Officer, Matthew Walsh, our Chief Financial Officer, and Juan Camilo, our homeowner Ferrara Organon's, Head of R&D.
Today, it will be referencing a presentation that will be visible during this call. For those of you on our webcast presentation will also be available following this call on the Events and Presentations section of our Organon Investor Relations website. Before we begin, I would like to caution listeners that certain information discussed by management during this conference call will include
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
